title: Effects of olanzapine on LPS-induced inflammation in rat primary glia cells.
abstract: Olanzapine (OLZ) is an atypical antipsychotic drug that also has mood-stabilizing effects. The mechanism of action of OLZ is not fully understood. Accumulating data suggest that inflammation plays a role in the pathophysiology of mental disorders and that psychotropic drugs exhibit some anti-inflammatory properties. This study was undertaken to examine the effects of OLZ on LPS-induced inflammation in rat primary glia cells. Glia cells were extracted from newborn rat brains. OLZ (1 or 50 µM) was added to culture medium at 6 or 72 h before addition of LPS for another 18 h, and levels of IL-10, prostaglandin (PG) E2, NO and TNF-α, and expression of cyclo-oxygensase (COX)-2 and inducible NO synthase (iNOS) were determined. Treatment with 50 µM OLZ (but not 1 µM) significantly decreased LPS-induced secretion of IL-10, PGE2 and TNF-α. In contrast, 50 µM OLZ significantly increased NO levels. OLZ did not alter the expression of COX-2 or iNOS in LPS-treated cells. These results suggest that OLZ differently affects the secretion of inflammatory mediators. Most of the significant effects of OLZ were obtained when 50 µM was used, which is a high and probably therapeutically irrelevant concentration. Therefore, under the conditions used in the present study OLZ seemed to lack a potent anti-inflammatory effect.
authors.affiliation: Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
authors.forename: Caroline
authors.initials: C
authors.lastname: Faour-Nmarne
authors.affiliation: Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel School for Community Health Professions, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel azab@bgu.ac.il.
authors.forename: Abed N
authors.initials: AN
authors.lastname: Azab
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D014150:Antipsychotic Agents / Q000494:pharmacology*; D001569:Benzodiazepines / Q000494:pharmacology*; D002478:Cells, Cultured; D015232:Dinoprostone / Q000378:metabolism; D006801:Humans; D007249:Inflammation / Q000188:drug therapy* / Q000276:immunology; D016753:Interleukin-10 / Q000378:metabolism; D008070:Lipopolysaccharides / Q000378:metabolism; D001523:Mental Disorders / Q000188:drug therapy* / Q000276:immunology; D009457:Neuroglia / Q000187:drug effects* / Q000276:immunology; D000077152:Olanzapine; D051381:Rats; D017208:Rats, Wistar; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D014150:Antipsychotic Agents; D008070:Lipopolysaccharides; D014409:Tumor Necrosis Factor-alpha; D001569:Benzodiazepines; D016753:Interleukin-10; D015232:Dinoprostone; D000077152:Olanzapine
keywords: Cytokines; inflammation; olanzapine; prostaglandins; psychotropic drugs